This legislation aims to enhance competition in the pharmaceutical market by preventing brand name drug companies from engaging in practices that delay the introduction of cheaper generic and biosimilar medications. Specifically, it targets "pay-for-delay" agreements, where brand companies compensate generic manufacturers to postpone their market entry, thereby keeping drug prices high and limiting consumer access to affordable options. Key provisions include a clear prohibition against agreements that result in anticompetitive effects, particularly reverse payment agreements.